NASDAQ:SMMT opened at $2.08 on Tuesday. Summit Therapeutics has a twelve month low of $1.88 and a twelve month high of $8.70. The company has a 50-day moving average of $2.56 and a 200-day moving average of $3.53. The firm has a market cap of $204.09 million, a price-to-earnings ratio of -2.17 and a beta of 0.78.
Summit Therapeutics (NASDAQ:SMMT – Get Rating) last posted its quarterly earnings data on Thursday, March 17th. The company reported ($0.28) earnings per share for the quarter. Summit Therapeutics had a negative net margin of 493.14% and a negative return on equity of 95.94%. The business had revenue of $4.84 million for the quarter.
About Summit Therapeutics (Get Rating)
Summit Therapeutics Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.
- Get a free copy of the StockNews.com research report on Summit Therapeutics (SMMT)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.